Micron, Inc, a Japan-based CRO leader in Imaging and clinical trials, and Global Regulatory Partners Inc, a leading provider of clinical development, regulatory affairs and compliance services for the Pharma, Biotech and MedTech industries worldwide, are pleased to announce the signature of a strategic partnership agreement, that will allow both parties to leverage their respective expertise and strengths, and offer End-to-End clinical and regulatory affairs services to their clients in Japan, APAC region and USA, and more specially in the radiopharmaceutical area.

Micron Inc, is the only CRO in Japan that can provide comprehensive support for clinical trials using medical imaging, including not only image analysis services in the clinical development of pharmaceuticals and medical devices, but also for clinical research and investigator-initiated clinical trials, imaging biomarker (iBM) developments, image analysis software distribution, and PET manufacturing facility establishment.

Global Regulatory Partners, Inc (GRP) provides a wide range of regulatory affairs, clinical development, quality and safety services to Pharma, Biotech and MedTech industries globally. Its Japanese subsidiary (GRP-GK Japan) was established as MAH in October 2016, and has been supporting multiple foreign companies accessing the Japanese market with limited risk and record timing.

“We all know the multiple challenges that radiopharmaceuticals present for investigators, regulators and users, because of their characteristics, mechanism of action, radioactivity and very short shelf life.
However, I truly believe that both, Micron and Global Regulatory Partners, have a unique expertise which is: Clinical Development and Registration of Radiopharmaceuticals drugs. By working together we will better serve our clients and allow them to bring new radiopharmaceutical drugs to the market in a shorter timelines, and consequently help many patients that are in real need of these new therapies”. said Dr. Suzan Davis, CEO of Global Regulatory Partners, Inc.

“I’m really, excited about this new partnership with Micron Inc, because it will provide our existing and future radiopharmaceutical clients access to a robust set of comprehensive and integrated clinical trial capabilities in addition to our regulatory affairs capabilities and expertise in radiopharmaceuticals, across Japan, Asia and globally as well,” said Yoshi Shinoki, General Manager GRP Japan.